<DOC>
	<DOCNO>NCT01645280</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ustekinumab CNTO 1959 reduce sign symptom disease patient active rheumatoid arthritis ( RA ) despite concomitant methotrexate ( MTX ) therapy evaluate safety ustekinumab CNTO 1959 population .</brief_summary>
	<brief_title>A Study Effectiveness Safety Ustekinumab ( STELARA ) CNTO 1959 Administered Under Skin Patients With Active Rheumatoid Arthritis , Despite Existing Methotrexate Therapy</brief_title>
	<detailed_description>This randomize ( patient assign treatment chance ) , double-blind ( study personnel patient know treatment assigned patient ) , multicenter , placebo-controlled ( placebo treatment identical appearance study agent , contain active ingredient ) , dose-ranging study . Approximately 250 patient randomly assign 1 5 treatment group . The maximum length study participation 54 week , include 6-week screening period . The end study last follow-up visit last patient . Study visit evaluation occur , patient safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have RA least 6 month prior screen Have diagnosis RA accord revised 1987 criterion American Rheumatism Association Be positive either anticyclic citrullinated peptide antibody rheumatoid factor serum screen Have treat tolerate MTX least 6 month prior screen , MTX dose &gt; = 10 mg &lt; = 25 mg per week stable least 12 week prior first administration study agent Have active RA , define persistent disease activity follow criterion : least 6 swollen 6 tender joint time screen baseline ; serum Creactive protein ( CRP ) &gt; = 0.80 mg/dL screening . The investigator may consider patient eligible CRP value least 0.80 mg/dL single repeat test screening period If use oral corticosteroid , must stable dose &lt; = 10 mg/day prednisone equipotent dose another oral corticosteroid least 2 week prior first administration study agent . If use corticosteroid Week 0 , patient must receive oral corticosteroid least 2 week prior first administration study agent If use nonsteroidal antiinflammatory drug ( NSAIDs ) analgesic regularly RA , patient must stable dose least 2 week prior first administration study agent . If use NSAIDs analgesic RA Week 0 , patient must receive NSAIDs analgesic RA least 2 week prior first administration study agent Has inflammatory disease , include limited psoriatic arthritis , ankylose spondylitis ( AS ) , systemic lupus erythematosus , Lyme disease , might confound evaluation benefit study agent therapy Has current sign symptom liver insufficiency cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , psychiatric , metabolic disturbance severe , progressive , uncontrolled Has know malignancy history malignancy ( exception basal cell carcinoma , squamous cell carcinoma situ skin , cervical carcinoma situ treat evidence recurrence , squamous cell carcinoma skin treat evidence recurrence within 5 year prior first administration study agent ) Has history lymphoproliferative disease , include lymphoma , sign suggestive possible lymphoproliferative disease lymphadenopathy unusual size location , clinically significant splenomegaly Has know allergy , hypersensitivity , intolerance ustekinumab CNTO 1959 inactive ingredient Has ever receive approved investigational biologic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Active rheumatoid arthritis</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>STELARA</keyword>
	<keyword>CNTO 1959</keyword>
</DOC>